Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

343 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early vascular healing with rapid breakdown biodegradable polymer sirolimus-eluting versus durable polymer everolimus-eluting stents assessed by optical coherence tomography.
Tada T, Byrne RA, Schuster T, Cuni R, Kitabata H, Tiroch K, Dirninger A, Gratze F, Kaspar K, Zenker G, Joner M, Schömig A, Kastrati A. Tada T, et al. Among authors: joner m. Cardiovasc Revasc Med. 2013 Mar-Apr;14(2):84-9. doi: 10.1016/j.carrev.2012.12.003. Epub 2013 Jan 24. Cardiovasc Revasc Med. 2013. PMID: 23352095 Clinical Trial.
Differential relative efficacy between drug-eluting stents in patients with bare metal and drug-eluting stent restenosis; evidence in support of drug resistance: insights from the ISAR-DESIRE and ISAR-DESIRE 2 trials.
Byrne RA, Cassese S, Windisch T, King LA, Joner M, Tada T, Mehilli J, Pache J, Kastrati A. Byrne RA, et al. Among authors: joner m. EuroIntervention. 2013 Nov;9(7):797-802. doi: 10.4244/EIJV9I7A132. EuroIntervention. 2013. PMID: 23687095 Free article.
Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients.
Tada T, Byrne RA, Simunovic I, King LA, Cassese S, Joner M, Fusaro M, Schneider S, Schulz S, Ibrahim T, Ott I, Massberg S, Laugwitz KL, Kastrati A. Tada T, et al. Among authors: joner m. JACC Cardiovasc Interv. 2013 Dec;6(12):1267-74. doi: 10.1016/j.jcin.2013.06.015. JACC Cardiovasc Interv. 2013. PMID: 24355117 Free article.
Randomized comparison of biolimus-eluting stents with biodegradable polymer versus everolimus-eluting stents with permanent polymer coatings assessed by optical coherence tomography.
Tada T, Kastrati A, Byrne RA, Schuster T, Cuni R, King LA, Cassese S, Joner M, Pache J, Massberg S, Schömig A, Mehilli J. Tada T, et al. Among authors: joner m. Int J Cardiovasc Imaging. 2014 Mar;30(3):495-504. doi: 10.1007/s10554-014-0376-1. Epub 2014 Jan 23. Int J Cardiovasc Imaging. 2014. PMID: 24452729 Clinical Trial.
Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: results from the ISAR-DESIRE 2 trial.
Kufner S, Byrne RA, de Waha A, Schulz S, Joner M, Laugwitz KL, Kastrati A; Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2, (ISAR-DESIRE 2) Investigators. Kufner S, et al. Among authors: joner m. Cardiovasc Revasc Med. 2014 Mar;15(2):69-75. doi: 10.1016/j.carrev.2014.02.001. Epub 2014 Feb 15. Cardiovasc Revasc Med. 2014. PMID: 24684757 Clinical Trial.
343 results